

Contents of *The American Journal of Psychiatry*

October 1995

Volume 152

Editorial

Why be concerned about recruitment? *James H. Scully* 1413

Images in Neuroscience

Neuroimaging, I: PET with [¹⁸F]fluorodeoxyglucose. *Essay by Carol A. Tamminga* 1415

Special Article

Decline of U.S. medical student career choice of psychiatry and what to do about it. *Frederick S. Sierles and Michael Alan Taylor* 1416

Regular Articles

Progress toward achieving a common language in psychiatry, II: results from the international field trials of the ICD-10 diagnostic criteria for research for mental and behavioral disorders. *Norman Sartorius, T. Bedirhan Üstün, Ailsa Korten, John E. Cooper and Jenny van Drimmelen* 1427

DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. *Robert M. Goisman, Meredith G. Warshaw, Gail S. Steketee, Eugene J. Fierman, Malcolm P. Rogers, Idell Goldenberg, Naomi J. Weinshenker, Russell G. Vasile and Martin B. Keller* 1438

D₁, D₂, and 5-HT₂ receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. *Anna-Lena Nordström, Lars Farde, Svante Nyberg, Per Karlsson, Christer Halldin and Göran Sedvall* 1444

Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models. *Victor Peralta and Manuel J. Cuesta* 1450

Negative, psychoticism, and disorganised dimensions in patients with familial schizophrenia or bipolar disorder: continuity and discontinuity between the major psychoses. *Michel Maziade, Marc-André Roy, Maria Martinez, Denis Cliche, Jean-Pierre Fournier, Yvon Garneau, Luc Nicole, Noël Montgrain, Claude Dion, Anne-Marie Ponton, Anne Potvin, Jean-Charles Lavallée, Arthur Pirès, Stéphane Bouchard, Pierrette Boutin, François Brisebois and Chantal Mérette* 1458

Clinical effects of recent cocaine use on patients with acute schizophrenia. *Mark R. Serper, Murray Alpert, Nancy A. Richardson, Sean Dickson, Michael H. Allen and Amy Werner* 1464

SPECT findings on psychosis in Alzheimer's disease. *Kathryn J. Kotrla, Ranjit C. Chacko, Robert G. Harper, Satish Jhingran and Rachelle Doody* 1470

Multicenter clinicopathological correlation in dementia. *Jeff Victoroff, Wendy J. Mack, Scott A. Lyness and Helena C. Chui* 1476

Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. *Hugh C. Hendrie, Benjamin O. Osuntokun, Kathleen S. Hall, Adesola O. Ogunniyi, Siu L. Hui, Frederick W. Unverzagt, Oyewusi Gureje, Cynthia A. Rodenberg, Olusegun Baiyewu, Beverly S. Musick, Abiodun Adeyinka, Martin R. Farlow, S. O. Oluwole, C. Andrew Class, O. Komolafe, Allison Brashear and Vicki Burdine* 1485

Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. *Jesse R. Fann, Wayne J. Katon, Jay M. Uomoto and Peter C. Esselman* 1493

Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. *Andrew A. Nierenberg, Nancy E. McLean, Jonathan E. Alpert, John J. Worthington, Jerrold F. Rosenbaum and Maurizio Fava* 1500

Individual psychotherapies for depressed HIV-positive patients. *John C. Markowitz, Gerald L. Klerman, Kathleen F. Clougherty, Lisa A. Spielman, Lawrence B. Jacobsberg, Baruch Fishman, Allen J. Frances, James H. Kocsis and Samuel W. Perry III* 1504

Images in Psychiatry

Eli Robins, 1921-1994. *Essay by Samuel B. Guze* 1510

Brief Reports

Predictors of response to lithium in patients with psychoses. *Lisa W. Schexnayder, Jack Hirschowitz, Fred J. Sautter and David L. Garver* 1511

Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. *Anthony J. Rothschild* 1514

Auditory sensory ('echoic') memory dysfunction in schizophrenia. *Rael D. Strous, Nelson Cowan, Walter Ritter and Daniel C. Javitt* 1517

Use of prescription psychotropic drugs among suicide victims in New York City. *Peter M. Marzuk, Kenneth Tardiff, Andrew C. Leon, Charles S. Hirsch, Marina Stajic, Nancy Hartwell and Laura Portera* 1520

The Royal College of Psychiatrists'
Journal of Continuing
Professional Development



Advances in Psychiatric Treatment

Editor: Andrew Sims, *Director of
Continuing Professional Development*

This innovative new bi-monthly journal has been designed to promote continuing professional development in psychiatry. Each issue will include articles dealing with physical and psychological treatments, one of the specialties, and management topics.

This will be essential reading for every practising mental health professional who needs to be kept informed of current ideas, techniques and developments in psychiatry.

Subscription rate for **Volume 1, 1994/5**
(8 issues starting September 1994):

Europe, including UK £50.00

USA US\$80.00 Elsewhere £60.00

Full airmail £6/\$10 extra

*To enter your subscription or to obtain a
sample copy of APT, contact:*

Publications Subscription Department,
Royal Society of Medicine Press Limited,
PO Box 9002, London W1M 0ZA, UK.

Tel: (+44) 0171 290 2927/8;

Fax: (+44) 0171 290 2929

Epilim Oral Prescribing Information

Presentation Epilim 200 Enteric Coated and Epilim 500 Enteric Coated: Enteric coated tablets containing 200mg, and 500mg Sodium Valproate Ph.Eur. respectively. Epilim Crushable Tablets containing 100mg Sodium Valproate Ph.Eur. Epilim Syrup and Epilim Liquid (sugar free) both containing 200mg Sodium Valproate Ph.Eur. per 5ml. Epilim Chrono 200, Epilim Chrono 300, and Epilim Chrono 500: Controlled release tablets containing a mixture of Sodium Valproate Ph.Eur. and Valproic Acid Fr.P. equivalent to 200mg, 300mg, and 500mg Sodium Valproate respectively. **Indications** Oral formulations of Epilim are indicated for all types of epilepsy. In women of child bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and administration** *Adults:* the dose should be titrated at three day intervals until seizure control is achieved. Initially 600mg a day increasing in steps of 200mg to a maximum dose of 2500mg per day. *Children over 20kg:* initially 400mg a day increasing in steps to a maximum dose of 35mg/kg/day. *Children under 20kg:* initially 20mg/kg/day - the dose may be increased in steps to a maximum of 40mg/kg/day provided that plasma levels are monitored. Epilim Chrono may be given once or twice daily. All other formulations should be given twice daily. **Combination therapy:** levels of Epilim and co-administered anticonvulsants may be affected and optimum dosage is determined by seizure control. **Contraindications, Warnings, etc.** *Contraindications* Active liver disease, family history of severe liver disease, hypersensitivity to valproate. *Side effects* Impaired hepatic function, particularly in children, occasionally leading to hepatic failure - treatment should be withdrawn in patients who suddenly develop symptoms compatible with hepatic disease such as nausea, anorexia, jaundice or malaise. Hyperammonaemia with or without hepatic dysfunction. Blood dyscrasia - impaired platelet function, thrombocytopenia, occasional leucopenia and red cell hypoplasia. Occasionally increased appetite, weight gain, transient hair loss, behavioural disturbances, alterations to the menstrual cycle and pancreatitis. Symptoms of intoxication include ataxia, tremor, and stupor. **Drug interactions** Epilim has significant interactions with phenytoin, lamotrigine and other anticonvulsants. Epilim may potentiate the effects of neuroleptics, MAOIs and other antidepressants, anticoagulants and salicylates. Cimetidine may inhibit the metabolism of Epilim. Epilim has no effect on the efficacy of oral contraceptives. **Pregnancy** An increased incidence of congenital abnormalities has been demonstrated in offspring born to mothers with epilepsy both untreated and treated, including those treated with sodium valproate. Neural tube defects have been reported in about 1% of offspring of women who have received valproate during the first trimester of pregnancy. Pregnancies should be screened for neural tube defects by estimation of alpha-fetoprotein and ultrasound. Folate supplementation has been shown to reduce the incidence of neural tube defects in the offspring of high risk women. **Legal category** P.O.M. **Further information** Epilim is hygroscopic - tablets should not be removed from their foil until they are used. Epilim Chrono is recommended in cases where plasma valproate levels are being measured on account of its pharmacokinetics. The effective therapeutic range for valproate is 40-100mg/l (278-694 micromol/l). **Product Licence Numbers** Epilim 200 Enteric Coated 11723/0018, Epilim 500 Enteric Coated 11723/0020, Epilim 100mg Crushable Tablets 11723/0017, Epilim Syrup 11723/0025, Epilim Liquid 11723/0024, Epilim Chrono 200 11723/0078, Epilim Chrono 300 11723/0021, Epilim Chrono 500 11723/0079. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.42, Epilim 500 Enteric Coated 100 tablets £16.04, Epilim 100mg Crushable Tablets 100 tablets £3.89, Epilim Syrup 300ml £5.89, Epilim Liquid 300ml £5.89, Epilim Chrono 200 100 tablets £7.70, Epilim Chrono 300 100 tablets £11.55, Epilim Chrono 500 100 tablets £19.25. **Address:** Sanofi Winthrop Ltd., One Onslow Street, Guildford, Surrey GU1 4YS. **Telephone:** (01483) 505515 **Fax:** (01483) 35432. Epilim, Epilim Chrono and the Chrono device are registered trade marks. **Date of preparation** August 1995.

References:

1. Chadwick D., *J. Neurol. Neurosurg. Psychiatry* 1994; 57: 264-277.
2. Gilham R.A., *Epilepsy Res.*, 1990; 7: 219-225.



NOW
ONCE-DAILY

Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.

Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,¹ it is well tolerated (particularly with regard to cognitive function)², and offers patients the convenience of once-daily dosing.

It helps people with epilepsy get on with their lives today, and look forward to tomorrow.



Epilim **CHRONO**[®]
Sodium Valproate Ph. Eur.
Valproic Acid Fr.P Controlled Release

**Once-daily management
for all forms of epilepsy**

Leadership isn't given. It's earned.



PROZAC
fluoxetine

The World's No. 1
prescribed
antidepressant brand

Further information is available on request from:
Dista Products Limited, Dextra Court, Chapel Hill,
Basingstoke, Hampshire RG21 5SY.

Legal Category: POM.

'PROZAC' is a Dista trade mark.

Date of preparation: August 1995



PZ683